The first Ugandan participants in a clinical safety study received an Oxford-developed Ebola vaccine last week.
Researchers vaccinated the first participants on October 6 in the city of Masaka, to the west of Lake Victoria.
The phase follows the launch of a first-in-human trial in the UK evaluating the same vaccine candidate.
They received the vaccine as part of an evaluation of the safety and efficacy of a Bundibugyo Ebola vaccine candidate developed by the Oxford Vaccine Group and the Pandemic Sciences Institute at the University of Oxford.
Development for this vaccine began in May this year in response to the ongoing Ebola outbreak in the Democratic Republic of the Congo.
The research, led by the group's Professor Teresa Lambe and Professor Simon Drysdale, is funded by the Coalition for Epidemic Preparedness Innovations.
No licenced vaccine for the Bundibugyo strain of Ebola virus currently exists.
The outbreak was declared a Public Health Emergency of International Concern by the World Health Organisation in May.
The vaccine will be evaluated initially for its safety and its ability to stimulate an immune response in healthy adult volunteers.
The trial does not, at this early stage, seek to determine whether the vaccine prevents infection or disease.
The Oxford Vaccine Group vaccinated the first volunteer in that study on July, 24 marking the first time the candidate had been administered to a person.
Together, the studies form part of an international programme seeking to close a significant gap in the medical response to Ebola outbreaks.
Confirmed cases in the Democratic Republic of the Congo’s Ebola outbreak have surpassed 9,000 as efforts to contain transmission falter, according to health ministry data released on Tuesday.
The ministry reported 9,066 confirmed cases and 4,381 deaths — a death toll equivalent to nearly half the confirmed cases.
Share